This single-center, randomized cross-over study explored for the first time the pharmacodynamic (PD) differences of the widely used basal insulin analogs detemir and glargine in WHO grade 2–3 obese individuals with type 2 diabetes. Here, INS is linked to type 2 diabetes mellitus.